Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $69.33 Consensus PT from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) have earned a consensus rating of “Buy” from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $69.33.

Several brokerages have recently issued reports on KYMR. Wells Fargo & Company began coverage on Kymera Therapeutics in a research report on Thursday, February 10th. They set an “overweight” rating and a $62.00 price objective for the company. Credit Suisse Group initiated coverage on Kymera Therapeutics in a report on Thursday. They set an “outperform” rating and a $63.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on Kymera Therapeutics in a report on Thursday, March 10th. They set a “neutral” rating and a $44.00 target price on the stock. Zacks Investment Research raised Kymera Therapeutics from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Wednesday, February 16th. Finally, Morgan Stanley dropped their target price on Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 2nd.

Shares of NASDAQ KYMR opened at $31.35 on Friday. The stock has a 50 day simple moving average of $38.20 and a 200-day simple moving average of $47.70. The company has a market cap of $1.62 billion, a PE ratio of -15.22 and a beta of 2.01. Kymera Therapeutics has a 12-month low of $29.81 and a 12-month high of $69.12.

Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last issued its quarterly earnings data on Thursday, February 24th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.30). The business had revenue of $15.30 million for the quarter, compared to analyst estimates of $21.31 million. Kymera Therapeutics had a negative return on equity of 27.16% and a negative net margin of 137.60%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. As a group, equities research analysts forecast that Kymera Therapeutics will post -2.32 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in Kymera Therapeutics by 11.7% during the 4th quarter. BlackRock Inc. now owns 3,397,540 shares of the company’s stock worth $215,709,000 after acquiring an additional 357,109 shares during the last quarter. BVF Inc. IL raised its position in shares of Kymera Therapeutics by 20.9% during the third quarter. BVF Inc. IL now owns 3,180,658 shares of the company’s stock valued at $186,832,000 after buying an additional 550,000 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Kymera Therapeutics by 198.1% during the third quarter. Wellington Management Group LLP now owns 2,467,935 shares of the company’s stock valued at $144,966,000 after buying an additional 1,639,994 shares during the last quarter. State Street Corp raised its position in shares of Kymera Therapeutics by 14.0% during the fourth quarter. State Street Corp now owns 1,641,762 shares of the company’s stock valued at $104,235,000 after buying an additional 201,986 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its position in shares of Kymera Therapeutics by 17.0% during the third quarter. Rock Springs Capital Management LP now owns 732,927 shares of the company’s stock valued at $43,052,000 after buying an additional 106,400 shares during the last quarter. Hedge funds and other institutional investors own 77.73% of the company’s stock.

About Kymera Therapeutics (Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More